(Q36001688)

11 August 2017

Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes (English)

1 reference

11 August 2017

0 references

4

Craig Kollman

1 reference

11 August 2017

1

Linda A DiMeglio

1 reference

11 August 2017

10

Bruce Buckingham

1 reference

11 August 2017

3

Roy W Beck

1 reference

11 August 2017

5

Katrina J Ruedy

1 reference

11 August 2017

Peiyao Cheng

2

1 reference

11 August 2017

Robert Slover

6

1 reference

11 August 2017

Tandy Aye

7

1 reference

11 August 2017

Stuart A Weinzimer

8

1 reference

11 August 2017

Andrew A Bremer

9

1 reference

11 August 2017

Diabetes Research in Children Network (DirecNet); Type 1 Diabetes TrialNet Study Group

11

1 reference

11 August 2017

language of work or name

1 reference

27 February 2015

1 reference

11 August 2017

1 reference

11 August 2017

17

1 reference

11 August 2017

237-243

1 reference

11 August 2017

4

1 reference

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Beta-cell mass and type 1 diabetes: going, going, gone?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

beta-cell function in children with diabetes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4551616

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

23 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FPEDI.12271

The transient effect of strict glycaemic control on B cell function in newly diagnosed Type 1 (insulin-dependent) diabetic patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FPEDI.12271

Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. The DCCT Research Group

21 January 2018

1 reference

12 December 2020

The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group

1 reference

12 December 2020

Natural course of insulin sensitivity and insulin reserve in early insulin-dependent diabetes mellitus

1 reference

12 December 2020

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Identifiers

DOI

10.1111/PEDI.12271

1 reference

11 August 2017

1 reference

11 August 2017

1 reference